Edition:
United States

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

246.40CHF
5:15am EDT
Change (% chg)

CHF0.60 (+0.24%)
Prev Close
CHF245.80
Open
CHF244.20
Day's High
CHF246.80
Day's Low
CHF244.20
Volume
7,106
Avg. Vol
29,150
52-wk High
CHF255.00
52-wk Low
CHF209.40

Select another date:

Mon, Aug 20 2018

Photo

Roche's Alecensa latest beneficiary of faster China drug approvals

ZURICH Roche's Alecensa lung cancer medicine became the latest beneficiary of China's efforts to speed up approvals in the world's second-biggest drug market, which is gaining importance for global pharmaceuticals companies' growth plans.

Roche's Alecensa latest beneficiary of faster China drug approvals

ZURICH, Aug 20 Chinese regulators are speeding up drug approvals, with Roche's Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies' growth plans.

BRIEF-Roche Canada Says Health Canada Approves Hemlibra For Hemophilia A Patients With Inhibitors

* HEALTH CANADA APPROVES HEMLIBRA® FOR HEMOPHILIA A PATIENTS WITH INHIBITORS Source text for Eikon: Further company coverage:

Roche lifts veil on patent that earned it billions but soon expires

ZURICH Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.

Roche lifts veil on patent that earned it billions but soon expires

ZURICH, July 26 Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.

Upbeat Roche bests rival Novartis as new drugs fuel growth

ZURICH Swiss drugmaker Roche on Thursday outshone crosstown rival Novartis by boosting its 2018 sales outlook, helped by new medicines in a year when many feared patent expirations and cheaper copies would put growth at risk.

UPDATE 2-Upbeat Roche bests rival Novartis as new drugs fuel growth

* Shares rise 3 percent (Adds comment from CEO, analyst, details about rivals)

Roche raises outlook for 2018 as new drugs gain traction

ZURICH, July 26 Swiss drugmaker Roche lifted its 2018 outlook on Thursday for the second time this year, after first-half sales and profit easily beat analyst expectations on the strength of newer drugs including multiple sclerosis treatment Ocrevus.

BRIEF-Puretech Health Announces Collaboration With Roche

* PURETECH HEALTH ANNOUNCES COLLABORATION WITH ROCHE TO ADVANCE TECHNOLOGY FOR ORAL ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES

Roche gets breakthrough status for Alzheimer's test Elecsys

ZURICH The U.S. Food and Drug Administration has granted Roche an accelerated review for its Elecsys product used to diagnose Alzheimer's disease, the Swiss drugmaker said on Friday.

Select another date: